Proliferative effects of urogastrone-EGF on the intestinal epithelium

R A GOODLAD, T J G WILSON, W LENTON, H GREGORY, K G MCCULLAGH, AND N A WRIGHT

From the Cancer Research Campaign Cell Proliferation Unit, Department of Histopathology, Royal Postgraduate Medical School, Hammersmith Hospital, London, ICI, Alderley Park, Macclesfield, and G D Searle, High Wycombe, Bucks

SUMMARY The effects of B-urogastrone/human epidermal growth factor on intestinal epithelial cell proliferation were studied in rats in which intestinal cell proliferation was reduced to a steady state basal level (by maintaining the rats on total parenteral nutrition). Increasing doses of urogastrone progressively raised the two hour collection of metaphases and intestinal weights. The crypt cell production rate was measured in animals maintained parenterally with or without urogastrone, and in rats fed a standard laboratory ration. Continuous infusion of 15 μg per rat per day of recombinant beta urogastrone (a dose which has a minimal effect on gastric acid secretion) significantly increased cell proliferation and intestinal tissue weights throughout the gastrointestinal tract. Intravenous infusion of urogastrone was also effective in restoring cell proliferation when it was infused after the intestine had become hypoproliferative. Urogastrone administered through an intragastric cannula thrice daily had no significant effect on either intestinal weight, crypt cell production rate, or metaphase collection.

β-urogastrone (human epidermal growth factor, URO-EGF) is a natural human polypeptide which has similar properties to rat and mouse EGF. While the growth promoting actions of URO-EGF in vitro have been well characterised, its role in vivo is uncertain: URO-EGF stimulates the proliferation and maturation of the neonatal intestine, where it also increases the activity of intestinal ornithine decarboxylase. The presence of URO-EGF in a variety of body fluids, including saliva, plasma and milk, its production by the salivary and Brunner's glands, the demonstration of URO-EGF receptors in intestinal epithelial cells and its reported cytoprotective effects on the duodenal mucosa all suggest that it has a role in the control of gastrointestinal homeostasis—quite apart from its ability to inhibit gastric acid secretion.

Previous studies of the effects of URO-EGF on the intestine have yielded conflicting results which could be due to the use of inappropriate animal models. The best model is probably the rat maintained by isocaloric total parenteral nutrition (TPN), as the intestine of the TPN rat is in a steady state at a basal level of cell proliferation, so that the direct and indirect effects of food (luminal nutrition), and the effects of endogenous secretions, are considerably reduced.

This model was used to investigate the effects of recombinant URO-EGF on cell proliferation in five experiments. The first was a dose response study. The second quantified the effects of an intravenous dose of URO-EGF on crypt cell production rate in a maintenance experiment. The third experiment investigated the time course of the effects of URO-EGF when given after the intestine had atrophied (intervention). The fourth and fifth investigations studied the effects of the intragastric administration of URO-EGF.

URO-EGF stimulated intestinal epithelial cell proliferation and growth at all sites of the gastrointestinal tract, in a dose dependent manner, the most marked effects being observed in the stomach and colon. A relatively low dose of URO-EGF, which should not inhibit gastric acid secretion, significantly

Address for correspondence: Dr R A Goodlad, Dept of Histopathology, Royal Postgraduate Medical School (RPMS), Hammersmith Hospital, Ducane Road, London.
Fig. 1  Effects of 10 days intravenous infusion of various doses of urogastrone on 2-hour metaphase collection. Sites were defined by their position in the gut (as percentage length of the small intestine or colon), thus 10% SI = 10% of the length of the small intestine. The dotted line shows the values obtained in orally fed rats. There were 4 animals per group.

* = significantly higher than the TPN group $p < 0.05$; ** = significantly higher than the TPN group $p < 0.01$; *** = significantly higher than the TPN group $p < 0.001$. 
increased the crypt cell production rate (CCPR) throughout the intestine, with the CCPR's of the stomach and colon increasing to the levels observed in orally-fed rats. URO-EGF was also effective in stimulating proliferation, once hypoplasia had become established. Intragastric administration, however, had no effect.

**Results**

**INTRAVENOUS UROGASTRONE DOSE RESPONSE STUDY**

The effects of 0 to 300 \( \mu g \)/rat/day of URO-EGF on the two hour collection of arrested metaphases were determined in a dose response study in parenterally maintained rats.

There was a highly significant \( (p < 0.001) \) correlation \( (r = 0.997) \) between plasma URO-EGF and the dose of URO-EGF administered. Plasma URO-EGF rose by 37.8 \( \pm \) 1.2 pg/ml per \( \mu g \) administered per rat per day.

There was no evidence of any effect at the lowest dose (3 \( \mu g \)/rat/day) (Fig. 1), however, there were significant increases with the 15 \( \mu g \)/rat/day group in all the intestinal sites studied except the mid and distal colon. This proliferative response continued in a dose responsive manner in most sites. The most pronounced effects were seen in the colon.

**INTRAVENOUS UROGASTRONE (MAINTENANCE)**

A dose of 15 \( \mu g \)/rat/day was chosen for an investigation utilising the crypt cell production rate (CCPR) method. The aim of the study was to investigate whether continuous infusion of URO-EGF, at a dose below that needed to inhibit gastric acid secretion, could maintain epithelial cell proliferation at the levels observed in orally-fed rats when the rats were fed parenterally.

**Methods**

**URO-EGF**

The URO-EGF was recombinant polypeptide (supplied by ICI and G D Searle) derived from the expression of a synthetic gene in *E. coli* and purified to > 97%. It had the same amino acid sequence and biological activity as natural human URO-EGF.

**Animals**

Male 200 g Wistar rats (Olac Ltd., Blackthorn, Oxon, UK) were housed individually in wire bottomed Perspex cages made up in the RPMS workshops. The rats were maintained on the respective treatments for 10 days, unless stated otherwise. Rats were anaesthetised and the right external jugular vein cannulated with a silastic catheter, which was brought round to the back of the neck by a skin tunnel and connected via a Harvard skin button and stainless steel tether (Harvard Apparatus Ltd, Firecroft Way, Kent, UK) to a Harvard miniature fluid swivel joint.

**TPN DIET**

One litre of the diet contained the following: 714 ml Vamin glucose, 92 ml intralipid 20% (Kabivitrum Ltd, Riverside Way, Uxbridge) 140 ml dextrose 50%, vitamins and salts. Each rat was infused with 60 ml/day giving 1.8 g N, as purified amino acids, equivalent to 11.5 g of first class protein; 60 g lipid; 8.5 g glucose and 250 kcal per kg of rat per day.

**AUTOPSY PROCEDURE**

The rats were given 1 mg/kg vincristine sulphate (Eli Lilly, Basingstoke, UK) intravenously, and killed at timed intervals by injection of 12 mg of pentobarbitone and exsanguination. The stomach, caecum and samples of the small intestine and colon (as defined by their percentage length) were then weighed and fixed in Carnoy's fluid. The tissue was stained with the Feulgen reaction and the antral glands, intestinal crypts or colonic crypts were micro-dissected; the number of arrested metaphases in ten crypts was then counted and the mean values plotted against time after injection. The slope of the line, fitted by least squares linear regression, gave the crypt cell production rate (CCPR). For some studies the accumulation of metaphases over a two hour period was quantified to give an augmented mitotic index.
Fig. 3 Two hour metaphase collection (mean value for 10 crypts or glands) at various times after the administration of urogastrone (60 μg/rat/day). The sites were defined by the relative length of the small intestine (SI) and of colon. Rats were maintained by TPN for 4 days before the infusion of urogastrone. Dotted line shows the values obtained in orally fed rats.
Proliferative effects of urogastrone-EGF on the intestinal epithelium

Ten days of TPN significantly decreased (p < 0.01) the weights of the small intestine, caecum and colon and the CCPR (Fig. 2). 15 μg/rat/day of URO-EGF, infused intravenously, gave a mean plasma level of 1085 ± 276 pg/ml and significantly increased the relative weight of the stomach, small intestine and colon, when compared with the TPN group (p < 0.01, 0.001, 0.05), and significantly increased the CCPR at all sites in the gastrointestinal tract (Fig. 2).

INTERVENTION TIME COURSE STUDY

An intervention study was instigated in order to determine whether URO-EGF could also cause a proliferative response in the atrophic intestine, and if so, to investigate the time course of this response. Rats were maintained on TPN for four days, then given 60 μg/rat/day URO-EGF and killed at six hour intervals. Proliferation was quantified by the two hour collection of arrested metaphases. There was a general increase in tissue weights with time, and this was statistically significant (by analysis of variance) for the small intestine (p < 0.05) and the colon (p < 0.01). The effects of urogastrone on the accumulation of arrested metaphases is shown in Fig 2. There was a gradual increase in metaphases over the first 24 hours, becoming apparent 12 hours after the administration of urogastrone in the stomach and small intestine. There was, however, no evidence of increased cell proliferation in the colon until 18 hours after the administration of urogastrone.

INTRAGASTRIC ADMINISTRATION OF UROGASTRONE

The effects of intragastric infusion of URO-EGF were investigated. A tube was placed in the squamous stomach of the rats at the time of their jugular cannulation. This tube was then used to infuse URO-EGF at eight hour intervals. The CCPR was measured after 10 days of daily dosing with urogastrone at 15 μg/rat/day.

A further intragastric study was also carried out in which higher doses of URO-EGF (150 and 300 μg/rat/day) were used, incorporating the two hour metaphase arrest method. The daily intragastric infusion of 15 μg of urogastrone per rat had no effect on intestinal weight. The CCPR of the various

Table 1. Effects of intragastric urogastrone (15 μg/rat/day) crypt cell production rates.

<table>
<thead>
<tr>
<th>Site</th>
<th>Controls</th>
<th>+ URO-EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>0.59</td>
<td>0.38</td>
</tr>
<tr>
<td>10% of the length of</td>
<td>0.24</td>
<td>0.56</td>
</tr>
<tr>
<td>small intestine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50% of the length of</td>
<td>1.58</td>
<td>4.33</td>
</tr>
<tr>
<td>small intestine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90% of the length of</td>
<td>1.35</td>
<td>2.53</td>
</tr>
<tr>
<td>small intestine</td>
<td></td>
<td></td>
</tr>
<tr>
<td>50% of the length of</td>
<td>0.83</td>
<td>4.53</td>
</tr>
<tr>
<td>colon</td>
<td></td>
<td></td>
</tr>
<tr>
<td>90% of the length of</td>
<td>1.44</td>
<td>1.08</td>
</tr>
<tr>
<td>colon</td>
<td>2.78</td>
<td>5.01</td>
</tr>
</tbody>
</table>

There were 7 animals per group. The rats were on TPN (with or without URO-EGF) for 10 days.

Table 2. Effects of high doses of urogastrone (150 and 300 μg/rat/day) on the 2-hour collection of metaphases.

<table>
<thead>
<tr>
<th>Site</th>
<th>TPN</th>
<th>TPN + 150 μg URO-EGF</th>
<th>TPN + 300 μg URO-EGF</th>
</tr>
</thead>
<tbody>
<tr>
<td>Stomach</td>
<td>1.13</td>
<td>2.74</td>
<td>1.00</td>
</tr>
<tr>
<td>10% of the length of</td>
<td>2.4</td>
<td>2.2</td>
<td>2.2</td>
</tr>
<tr>
<td>small intestine</td>
<td>3.9</td>
<td>4.3</td>
<td>2.2</td>
</tr>
<tr>
<td>50% of the length of</td>
<td>2.05</td>
<td>6.1</td>
<td>1.3</td>
</tr>
<tr>
<td>small intestine</td>
<td>2.3</td>
<td>1.9</td>
<td>1.9</td>
</tr>
<tr>
<td>90% of the length of</td>
<td>3.83</td>
<td>7.3</td>
<td>4.8</td>
</tr>
<tr>
<td>colon</td>
<td>2.2</td>
<td>1.95</td>
<td>7.2</td>
</tr>
<tr>
<td>90% of the length of colon</td>
<td>5.8</td>
<td>2.2</td>
<td>2.6</td>
</tr>
</tbody>
</table>

The treatments lasted for 10 days. There were 4 animals in the control group, 5 in the 150 μg/rat/day group and 4 in the 300 μg/rat/day group.
Discussion

The dose of urogastrone used in the maintenance study (15 μg/rat/day) was considerably less than that used by most previous workers,5–7,15,16,18 and should only have had a minor influence on gastric acid secretion.14,20 This dose was, nonetheless, twice that used by some other workers17,19,21 whose results were somewhat equivocal in terms of the responses observed. However, these studies used starved animals, which are not an ideal model for proliferative studies.

The increase in proliferation in the intervention study was seen in the stomach and small intestine after 12 hours but in the colon only after 18 hours. Similar differences in the time course of proliferative increase have been observed in the intestine of starved mice after refeeding,27 which implied that the delay in colonic response was the consequence of the greater time taken for digesta to reach the colon. The present results suggest, however, that this delay reflects some inherent difference between the colon and the stomach-small intestine; perhaps due to the longer cell cycle time.28,39

The intragastric infusion of various doses of urogastrone had no significant effect on intestinal weights, CCPR or two hour metaphase collection. Although URO-EGF is taken up by the digestive tract in the neonate and weanling rat,30 recent evidence suggests that it is not absorbed in the adult gut.31,32 Whilst intragastric URO-EGF may have a cytoprotective action in the damaged gastric mucosa,13 the intestine was not damaged in this study.

The mechanisms or significance of the in vivo trophic action of URO-EGF are as yet unknown. Gastrointestinal epithelial cells possess URO-EGF receptors11,12 and the lack of response to luminal URO-EGF would suggest that they are located on the baso-lateral surface. It is also possible that these actions are mediated by another hormone or factor.

The present study has confirmed that TPN is associated with profound intestinal hypoplasia resulting in a new 'steady state'. We have quantified this in terms of crypt cell production. We have also shown that urogastrone was effective in reducing this hypoproliferative state, either when given during the initiation of TPN-associated hypoplasia (maintenance) or when hypoplasia had become established (intervention). These results suggest that URO-EGF could play an important role as a trophic factor in the maintenance of epithelial proliferation in the gastrointestinal tract.

We thank the Cancer Research Campaign for financial assistance.

References

15. Schieving LA, Yeh YC, Schieving LE. Circadian phase-dependent stimulatory effects of epidermal growth factor on deoxyribonucleic acid synthesis in the tongue.


Proliferative effects of urogastrone-EGF on the intestinal epithelium